Cash Flow Statement

Amortization Amortization Amortizatization of Intangibles Amortizatization of Intangibles Asset Writedowns and Impairment Asset Writedowns and Impairment Capital Expenditures Capital Expenditures Cash from Discontinued Operations Cash from Discontinued Operations Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Intangibles Change in Intangibles Change in Inventory Change in Inventory Change in Receivables Change in Receivables Divestments Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Share-based Compensation Share-based Compensation Shares Issued Shares Repurchased Short-Term Debt issuances

Daily Values

Growth Metrics

Others

Ratios

Quantum Biopharma (QNTM) Amortizatization of Intangibles (2024 - 2025)

Quantum Biopharma's Amortizatization of Intangibles history spans 2 years, with the latest figure at $13505.0 for Q3 2025.

On a quarterly basis, Amortizatization of Intangibles changed N/A to $13505.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $475124.0, a N/A change, with the full-year FY2024 number at $14560.0, changed N/A from a year prior.
Amortizatization of Intangibles hit $13505.0 in Q3 2025 for Quantum Biopharma, down from $118611.0 in the prior quarter.
Over the last five years, Amortizatization of Intangibles for QNTM hit a ceiling of $328448.0 in Q1 2025 and a floor of $13505.0 in Q3 2025.